ClinicalTrials.gg
CompletedNCT00890721Updated Aug 6, 2013Results posted

Study of Pain Control in Hemorrhoidectomy

A Phase 3 interventional study of SKY0402 and Placebo in Hemorrhoid, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-06.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Patients will get an injection of either SKY0402 or placebo during hemorrhoid surgery, and their pain and pain medicine use will be monitored.

02

Conditions studied

  • Hemorrhoid

Keywords

  • Hemorrhoid
  • Hemorrhoidectomy
  • Postoperative pain
  • Analgesia
03

In context

Hemorrhoids

239 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.

This study's enrollment of 189 is above the median of 100 across 184 interventional studies indexed under Hemorrhoids.

Browse Hemorrhoids studies →

Lead sponsor

Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years of age at the Screening visit
  • (ASA) class 1-3
  • Scheduled to have a two or three column excisional hemorrhoidectomy under general anesthesia using the Milligan-Morgan technique
  • For female subjects, surgically sterile or at least two years menopausal, or using an acceptable method of ; must have a documented negative blood or urine pregnancy test within 24 hours before surgery
  • Clinical lab values less than or equal to twice the or, if abnormal, deemed not per the Investigator.
  • Ability to understand the requirements of the study, provide written , abide by the study restrictions, and agree to return for the required assessments
  • Able to speak, read, and understand the language of all subject-facing documents, including the ICF and study questionnaires
  • Able and willing to comply with all study visits and procedures

Exclusion criteria

Exclusion Criteria:

  • Single-column hemorrhoidectomy or hemorrhoidectomy without an internal component
  • Body weight less than 50 kilograms (110 pounds)
  • History of or idiosyncratic reactions or amide-type local anesthetics, opioids, or propofol
  • Current painful physical condition or concurrent surgery other than hemorrhoids that may require analgesic treatment (such as non-steroidal anti-inflammatory drug [NSAID], opioid, selective serotonin reuptake inhibitor [SSRI], tricyclic antidepressant, gabapentin, pregabalin) in the postoperative period for pain that is not strictly related to the hemorrhoidectomy procedure and may confound the postoperative assessments
  • Concurrent fissurectomy
  • Use of any NSAID including selective COX-2 inhibitor, opioid, SSRI, tricyclic antidepressant, gabapentin, or pregabalin within three days of surgery
  • Use of acetaminophen within 24 hours of surgery
  • Chronic users of analgesic medications, including taking opioid medications for more than 14 days in the last 3 months, or non-opioid pain medications more than 5 times per week
  • History of, suspected, or known addiction to or abuse of drugs or alcohol within the past two years
  • Current use of glucocorticosteroids or use of within one month of enrollment into this study
  • infection or hepatitis
  • Currently pregnant, nursing, or planning to become pregnant during the course of the study or within one month of study drug administration
  • Any psychiatric, psychological, medical, or laboratory condition that the investigator feels makes the subject an inappropriate candidate for this clinical trial
  • Subjects who have received another drug within the longer of the last 30 days or 10 elimination half-lives
  • Previous participation in a SKY0402 study
  • Failure to pass drug and alcohol screen
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
189 participants (actual)

Study arms

  • Experimental
    SKY0402

    During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.

    Drug: SKY0402

  • Placebo comparator
    Placebo

    During the hemorrhoidectomy, 30cc Placebo injected into the wound.

    Drug: Placebo

Interventions

  • During the operation, 30cc of SKY0402 are injected into the wound.

    Also known as: EXPAREL

  • DrugPlacebo

    During the hemorrhoidectomy, 30cc Placebo injected into the wound.

    Also known as: saline 0.9%

06

What researchers measure

Primary outcomes

  1. The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo.

    To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain and respond to the following question: "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?"

    Time frame: 72 hours

Secondary outcomes

  1. Participants With Adverse Events Through 72 Hours or Serious Adverse Events Through 30 Days

    Time frame: 30 days

07

Results

Posted Aug 6, 2013

Participant flow

Participant flow — Overall Study
MilestoneSKY0402Placebo
Started9594
Completed9493
Not completed11

Outcome measures

PrimaryThe Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo.

To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain and respond to the following question: "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?"

Time frame:
72 hours
Reported as:
Least squares mean · units on a scale*hr
The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo.
units on a scale*hrSKY0402Placebo
The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo.141.8 ± 10.7202.5 ± 10.7
SecondaryParticipants With Adverse Events Through 72 Hours or Serious Adverse Events Through 30 Days
Time frame:
30 days

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SKY0402—0/94 (0%)2/94 (2.1%)
Placebo—1/93 (1.1%)5/93 (5.4%)
Most frequent serious events
Most frequent serious events
EventSKY0402Placebo
ThrombophlebitisVascular disorders0/941/93
Most frequent other events
Most frequent other events
EventSKY0402Placebo
Painful defaecationGastrointestinal disorders2/945/93

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SKY0402PlaceboTotal
<=18 years000
Between 18 and 65 years8686172
>=65 years9817
Age Continuous
Age Continuous(years)SKY0402PlaceboTotal
Mean48 ± 12.248.7 ± 1248.4 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)SKY0402PlaceboTotal
Female322759
Male6367130
Region of Enrollment
Region of Enrollment(participants)SKY0402PlaceboTotal
Poland363672
Serbia252550
Georgia343367
08

Study locations

1 site
  • Prof. Zbigniew Śledziński
    Gdansk, Poland
09

References and documents

Publications

  • Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3. PubMed 22900785 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 3 years 9 months after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2009
First posted
Apr 30, 2009
Start
May 2009
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results delay requested
Aug 25, 2010
Results first posted
Aug 6, 2013
Last update
Aug 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00890721
Responsible party
Sponsor
First posted
Apr 30, 2009
Start date
May 2009
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Aug 6, 2013
Last update
Aug 6, 2013

Study contacts

Zbigniew Śledziński, MD
principal investigator · General Surgery, Transplantology and Endocrinology Department, Gdansk

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion